All News
Gout Takeaways
The annual EULAR meeting just came to an end today. Rooms are gradually emptying out. People look both content to have updated their knowledge and relieved that four very busy days have concluded. Time to summarize.
Read ArticleEULAR 2018 - Day 1 Report
Highlights from the first day at EULAR include: canakinumab prevents acute gout; AS uveitis benefits from most TNFi; MRI does not improve T2Tor X-ray outcomes; baracitinib wins in SLE - maybe?; new lupus criteria; and lost survival in RA. Here's the RheumNow recap.
Read ArticleThe RheumNow Week in Review – Baricitinib Splash (6.7.18)
Dr. Jack Cush discusses the past week's news and journal articles featured on RheumNow.com - including reports on advance practice clinicians, baricitinib, gout, disease activity, hypomagnesemia and upadacitinib.
Read ArticleSons of Gout Study
The genetics and heritability of gout has suggested a higher risk in certain families. A UK cohort study examined the prevalence of gout and monosodium urate (MSU) crystal deposition among those at risk (sons of gout patients) for gout and found a high incidence of hyperuricemia and MSU crystal deposition.
Read ArticleThe RheumNow Week in Review – Modifiable Behavior (5.18.18)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. He discusses opioids, new approval for polyarticular JIA, running and osteoarthritis, and modifiable behaviors that influence outcomes.
Read ArticleThe Hazardous Highs and Lows of Uric Acid
Both high and low levels of uric acid were linked with increased risks of death, showing a U-shaped association between serum uric acid levels and all-cause, cardiovascular, and cancer mortality, Korean researchers reported.
Read ArticleUnmet Needs in Calcium Pyrophosphate Deposition Disease
Abhishek et al have written on the results of an international survey of crystal arthritis experts and identified the unmet needs regarding calcium pyrophosphate crystal deposition (CPPD) - research, classification, diagnosis and management.
Read ArticleThe RheumNow Week in Review -30 March 2018
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on drug regulatory decisions, fenofibrate and gout, Still's disease, TB and infection rates, SpA and hidradenitis suppurativa, and predicting methotrexate non-responders.
Read ArticleFIELD Study: Fenofibrate Reduces Uric Acid and Gout Risk
Lancet reports the results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study - where fenofibrate was shown to reduce uric acid by 20%, gout events by nearly 50% and may be useful in preventing gout in diabetes.
Read ArticleShoe Inserts Disappoint with Plantar Heel Pain
A report from the British Journal of Sports Medicine shows that commonly used drug store shoe inserts or customized orthotics are often ineffective in managing plantar heel pain.
Read ArticleTime to Rethink Gout as a Chronic Disease
The current issue of JAMA has a perspective article on Gout’s bad rap as dietary disease rather than the complex, chronic inflammatory disorder that is ineffectively treated in many.
Read ArticleDoes Dose Escalation Help in Gout?
Contrary to expectations, dose escalation of allopurinol among patients with gout did not improve survival, a 10-year observational study found.
Read ArticleCARES Study- More CV Deaths with Febuxostat
The CARES study was presented Monday at the American College of Cardiology meeting in Orlando and finds that while the rates of all major cardiovascular (CV) events were comparable between febuxostat or allopurinol, there were more CV deaths with febuxostat.
Read ArticleDSB – Safety Updates & Drug Shortages – March 2018
This edition of RheumNow's Drug Safey Bulletin includes drug safety news, FDA updates, FDA safety labeling changes and reported drug shortages.
Read ArticleThe RheumNow Week in Review - 2 March 2018
Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com.
Read ArticleGout Crystal Deposition is Deeper than its Measures
Dalbeth and colleagues have published that among gout patients without palpable tophic and despite long term allopurinol, nearly half have monosodium urate (MSU) as detected by Dual-energy CT (DECT). The total body urate deposition is even greater in those with higher sUA and evidence
Read ArticleProbenecid Benefits Heart Failure
In animal studies, probenecid was shown to have positive inotropic effects on the cardiomyocyte mediated by transient receptor potential vanilloid 2 activation.
Read ArticleThe RheumNow Week in Review - 23 February 2018
Dr Jack Cush reviews highlights from the past week on RheumNow.com. This week’s video is in two parts; for part Ii, go to https://buff.ly/2BM9MjL
Read ArticleT2T Improves Primary Care Gout Management
Researchers from Geisinger Medical center tested a pilot primary care gout management improvement intervention, and demonstrated significantly improved primary care gout management metrics when a treat to target approach was implemented.
Read ArticleThe RWCS - RheumNow Week in Review - 9 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes news and education from the RWCS meeting in Maui.
Read Article